Um estudo para investigar a eficácia e segurança do anifrolumabe em adultos com lúpus eritematoso cutâneo crônico e/ou subagudo (LAVENDER)
Um estudo multicêntrico, randomizado, duplo-cego, controlado por placebo, de fase III para avaliar a eficácia e segurança do anifrolumabe em adultos com lúpus eritematoso cutâneo crônico e/ou subagudo que são refratários e/ou intolerantes à terapia antimalárica
This study aims to evaluate the efficacy and safety of subcutaneous (SC) anifrolumab versus placebo in adult participants with chronic and/or subacute cutaneous lupus erythematosus (CLE).
Visão geral do estudo
Status
Status
Condições
Condições
Intervenção / Tratamento
Intervenção / Tratamento
Descrição detalhada
This is a multicenter, randomized, double-blind, placebo-controlled, Phase III study to evaluate the efficacy and safety of anifrolumab in adults with chronic and/or subacute CLE who are refractory and/or intolerant to antimalarial therapy. The study has a randomized, 24-week double-blind, placebo-controlled study period (Week 0 to Week 23), to evaluate the efficacy and safety of anifrolumab. The double-blind study period will be followed by an open-label, uncontrolled treatment period in which all participants will receive treatment with anifrolumab from Week 24 to Week 51. After the open-label treatment period, participants will enter a 12-week Safety Follow-up Period.
Tipo de estudo
Tipo de estudo
Inscrição (Real)
Inscrição
Estágio
Estágio
- Fase 3
Contactos e Locais
Locais de estudo
-
-
-
Berlin, Alemanha, 10117
- Research Site
-
Bochum, Alemanha, 44791
- Research Site
-
Dresden, Alemanha, 01307
- Research Site
-
Erlangen, Alemanha, 91054
- Research Site
-
Essen, Alemanha, 45147
- Research Site
-
Freiburg im Breisgau, Alemanha, 79104
- Research Site
-
Hanover, Alemanha, 30625
- Research Site
-
Kiel, Alemanha, 24105
- Research Site
-
Leipzig, Alemanha, 04103
- Research Site
-
Mainz, Alemanha, 55131
- Research Site
-
Marburg, Alemanha, 35043
- Research Site
-
Regensburg, Alemanha, 93053
- Research Site
-
Wuppertal, Alemanha, 42283
- Research Site
-
-
-
-
-
Ciudad de Buenos Aires, Argentina, 1221
- Research Site
-
Córdoba, Argentina, 5000
- Research Site
-
Córdoba, Argentina, X5004BAL
- Research Site
-
Quilmes, Argentina, 1878
- Research Site
-
San Miguel, Argentina, 1663
- Research Site
-
-
-
-
-
Kogarah, Austrália, 3168
- Research Site
-
Melbourne, Austrália, 3004
- Research Site
-
Mitcham, Austrália, 3132
- Research Site
-
Westmead, Austrália, 2145
- Research Site
-
Woolloongabba, Austrália, 04102
- Research Site
-
-
-
-
-
Belo Horizonte, Brasil, 30150-221
- Research Site
-
Porto Alegre, Brasil, 90035903
- Research Site
-
Rio de Janeiro, Brasil, 22470-220
- Research Site
-
Salvador, Brasil, 40150-150
- Research Site
-
São Paulo, Brasil, 05403-000
- Research Site
-
-
-
-
-
Sofia, Bulgária, 1784
- Research Site
-
Sofia, Bulgária, 1463
- Research Site
-
Sofia, Bulgária, 1528
- Research Site
-
-
-
-
British Columbia
-
Vancouver, British Columbia, Canadá, V5Z 1M9
- Research Site
-
-
Ontario
-
Hamilton, Ontario, Canadá, L8N 3Z5
- Research Site
-
Toronto, Ontario, Canadá, M5T 2S8
- Research Site
-
-
-
-
-
Osorno, Chile, 200025
- Research Site
-
Santiago, Chile, 7500571
- Research Site
-
Santiago, Chile, 130021
- Research Site
-
-
-
-
-
Changchun, China, 130021
- Research Site
-
Changsha, China, 410011
- Research Site
-
Chengdu, China, 610021
- Research Site
-
Chongqing, China, 400016
- Research Site
-
Dongguan, China, 523059
- Research Site
-
Guangzhou, China, 510120
- Research Site
-
Heilongjiang, China, 150086
- Research Site
-
Jinan, China, 250022
- Research Site
-
Shanghai, China, 200025
- Research Site
-
Shanghai, China, 200443
- Research Site
-
Shenzhen, China, 518053
- Research Site
-
Shenzhen, China, 518020
- Research Site
-
Shenzhen, China, 518052
- Research Site
-
Zhuzhou, China, 412007
- Research Site
-
Ürümqi, China, CN-830004
- Research Site
-
-
-
-
-
Barranquilla, Colômbia, 080020
- Research Site
-
Bogotá, Colômbia, 110221
- Research Site
-
-
-
-
-
Seoul, Coréia do Sul, 03080
- Research Site
-
Seoul, Coréia do Sul, 06591
- Research Site
-
Seoul, Coréia do Sul, 06973
- Research Site
-
-
-
-
-
Aarhus, Dinamarca, 641-8510
- Research Site
-
Copenhagen, Dinamarca, 2100
- Research Site
-
-
-
-
-
Košice, Eslováquia, 04001
- Research Site
-
Piešťany, Eslováquia, 92101
- Research Site
-
-
-
-
-
Barcelona, Espanha, 8035
- Research Site
-
Barcelona, Espanha, 08025
- Research Site
-
Castellon, Espanha, 12004
- Research Site
-
Granada, Espanha, 18012
- Research Site
-
L'Hospitalet de Llobregat, Espanha, 08907
- Research Site
-
Las Palmas de Gran Canaria, Espanha, 35010
- Research Site
-
Madrid, Espanha, 28034
- Research Site
-
Madrid, Espanha, 28041
- Research Site
-
Madrid, Espanha, 28040
- Research Site
-
Madrid, Espanha, 28006
- Research Site
-
Majadahonda, Espanha, 28222
- Research Site
-
Salamanca, Espanha, 37007
- Research Site
-
Seville, Espanha, 41014
- Research Site
-
Valencia, Espanha, 46014
- Research Site
-
Valencia, Espanha, 46017
- Research Site
-
Vigo, Espanha, 36200
- Research Site
-
-
-
-
Arizona
-
Phoenix, Arizona, Estados Unidos, 85028
- Research Site
-
-
California
-
Covina, California, Estados Unidos, 91722
- Research Site
-
La Jolla, California, Estados Unidos, 92037
- Research Site
-
Los Angeles, California, Estados Unidos, 90045
- Research Site
-
Los Angeles, California, Estados Unidos, 90089
- Research Site
-
Orange, California, Estados Unidos, 92868
- Research Site
-
San Francisco, California, Estados Unidos, 94143
- Research Site
-
-
Colorado
-
Aurora, Colorado, Estados Unidos, 80045
- Research Site
-
-
Connecticut
-
New Haven, Connecticut, Estados Unidos, 06519
- Research Site
-
-
District of Columbia
-
Washington D.C., District of Columbia, Estados Unidos, 20037
- Research Site
-
-
Florida
-
Fort Lauderdale, Florida, Estados Unidos, 33309
- Research Site
-
Miami, Florida, Estados Unidos, 33174
- Research Site
-
Plantation, Florida, Estados Unidos, 33324
- Research Site
-
-
Illinois
-
Chicago, Illinois, Estados Unidos, 60637
- Research Site
-
Chicago, Illinois, Estados Unidos, 60611
- Research Site
-
-
Indiana
-
Indianapolis, Indiana, Estados Unidos, 46202
- Research Site
-
-
Maryland
-
Baltimore, Maryland, Estados Unidos, 21287
- Research Site
-
-
Massachusetts
-
Boston, Massachusetts, Estados Unidos, 02114
- Research Site
-
Boston, Massachusetts, Estados Unidos, 02115-5817
- Research Site
-
-
Michigan
-
Ann Arbor, Michigan, Estados Unidos, 48109
- Research Site
-
Bloomfield Hills, Michigan, Estados Unidos, 48302
- Research Site
-
-
Minnesota
-
Rochester, Minnesota, Estados Unidos, 55905
- Research Site
-
-
Nebraska
-
Omaha, Nebraska, Estados Unidos, 68198-5885
- Research Site
-
-
New York
-
New York, New York, Estados Unidos, 10028
- Research Site
-
Rochester, New York, Estados Unidos, 14642
- Research Site
-
-
North Carolina
-
Charlotte, North Carolina, Estados Unidos, 28207
- Research Site
-
Statesville, North Carolina, Estados Unidos, 28625
- Research Site
-
-
Ohio
-
Cleveland, Ohio, Estados Unidos, 44195
- Research Site
-
-
Oregon
-
Portland, Oregon, Estados Unidos, 97239
- Research Site
-
-
Rhode Island
-
Providence, Rhode Island, Estados Unidos, 02903
- Research Site
-
-
South Carolina
-
Charleston, South Carolina, Estados Unidos, 29425
- Research Site
-
-
Texas
-
Dallas, Texas, Estados Unidos, 75390-8843
- Research Site
-
-
Virginia
-
Charlottesville, Virginia, Estados Unidos, 22903
- Research Site
-
Roanoke, Virginia, Estados Unidos, 24016
- Research Site
-
-
-
-
-
Iloilo City, Filipinas, 5000
- Research Site
-
Lipa, Filipinas, 4217
- Research Site
-
Manila, Filipinas, 1000
- Research Site
-
-
-
-
-
Bois-Guillaume, França, 76031
- Research Site
-
Dijon, França, 21000
- Research Site
-
Lyon, França, 69437
- Research Site
-
Montivilliers, França, 76290
- Research Site
-
Nantes, França, 44000
- Research Site
-
Paris, França, 75010
- Research Site
-
Paris, França, 75014
- Research Site
-
Paris, França, 75013
- Research Site
-
Paris, França, 75970
- Research Site
-
Poitiers, França, 86000, FR
- Research Site
-
Toulouse, França, 31059
- Research Site
-
-
-
-
-
Athens, Grécia, 12462
- Research Site
-
Athens, Grécia, 16121
- Research Site
-
-
-
-
-
Breda, Holanda, 4818 CK
- Research Site
-
Rotterdam, Holanda, 3015 GD
- Research Site
-
-
-
-
-
Brescia, Itália, 25123
- Research Site
-
Cona, Itália, 44124
- Research Site
-
Florence, Itália, 50121
- Research Site
-
Milan, Itália, 20132
- Research Site
-
Naples, Itália, 80138
- Research Site
-
Reggio Emilia, Itália, 42123
- Research Site
-
Roma, Itália, 00144
- Research Site
-
Rome, Itália, 00168
- Research Site
-
-
-
-
-
Chūōku, Japão, 104-8560
- Research Site
-
Fukuoka, Japão, 812-8582
- Research Site
-
Kanazawa, Japão, 920-8641
- Research Site
-
Kita-gun, Japão, 761-0793
- Research Site
-
Nagoya, Japão, 457-8510
- Research Site
-
Nagoya, Japão, 467-8602
- Research Site
-
Wakayama, Japão, 641-8510
- Research Site
-
Yokohama, Japão, 232-0024
- Research Site
-
tabashi City, Japão, 173-8606
- Research Site
-
-
-
-
-
Guadalajara, México, 44340
- Research Site
-
Guadalajara, México, 44610
- Research Site
-
Mexico City, México, 07760
- Research Site
-
Veracruz, México, 91910
- Research Site
-
-
-
-
-
Papatoetoe, Nova Zelândia, 2025
- Research Site
-
-
-
-
-
Katowice, Polônia, 40-851
- Research Site
-
Kielce, Polônia, 25-316
- Research Site
-
Ossy, Polônia, 40-027
- Research Site
-
Rzeszów, Polônia, 35-055
- Research Site
-
Warsaw, Polônia, 02-637
- Research Site
-
-
-
-
-
Braga, Portugal, 4710-243
- Research Site
-
Lisbon, Portugal, 1649-035
- Research Site
-
Porto, Portugal, 4099-001
- Research Site
-
-
-
-
-
Cambridge, Reino Unido, CB2 0QQ
- Research Site
-
Leeds, Reino Unido, LS2 9JT
- Research Site
-
London, Reino Unido, NW1 2PG
- Research Site
-
London, Reino Unido, SE5 9RS
- Research Site
-
London, Reino Unido, SE1 7EH
- Research Site
-
London, Reino Unido, NW3 2QG
- Research Site
-
Newcastle upon Tyne, Reino Unido, NE1 4LP
- Research Site
-
-
-
-
-
Bucharest, Romênia, 020125
- Research Site
-
Iași, Romênia, 700291
- Research Site
-
-
-
-
-
Belgrade, Sérvia, 11000
- Research Site
-
Kragujevac, Sérvia, 34000
- Research Site
-
-
-
-
-
Bangkok, Tailândia, 10330
- Research Site
-
Bangkok, Tailândia, 10700
- Research Site
-
Hat Yai, Tailândia, 90110
- Research Site
-
Khlong Luang, Tailândia, 12120
- Research Site
-
Khon Kaen, Tailândia, 40002
- Research Site
-
-
-
-
-
Kaohsiung City, Taiwan, 83301
- Research Site
-
Taichung, Taiwan, 404
- Research Site
-
Taipei, Taiwan, 10449
- Research Site
-
-
-
-
-
Cordaleo, Turquia (Türkiye), 35575
- Research Site
-
Istanbul, Turquia (Türkiye), 34098
- Research Site
-
Kayseri, Turquia (Türkiye), 38039
- Research Site
-
Samsun, Turquia (Türkiye), 55270
- Research Site
-
-
-
-
-
Cape Town, África do Sul, 7500
- Research Site
-
Johannesburg, África do Sul, 2193
- Research Site
-
-
-
-
-
Graz, Áustria, 8036
- Research Site
-
Innsbruck, Áustria, 6020
- Research Site
-
Linz, Áustria, 4020
- Research Site
-
Vienna, Áustria, 1130
- Research Site
-
-
Critérios de participação
Critérios de elegibilidade
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Descrição
Key inclusion criteria:
-
Participants must have a confirmed diagnosis of CLE. Diagnosis must be clinically and histologically confirmed with the following:
- CLASI-A total score ≥ 10 points at Screening and confirmed at randomization.
- Inadequate response or intolerant to antimalarial therapy.
-
Participants should have no medical history or signs or symptoms of active or prior tuberculosis infection (TB) and the same should reflect in chest radiograph or a chest CT scan result.
-
Contraceptive use by males and females should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.
Key exclusion criteria:
- History or evidence of suicidal ideation.
- Severe or life-threatening Systemic lupus erythematosus (SLE).
- Active SLE or Sjögren's Syndrome.
- Any active skin conditions other than CLE that may interfere with the study.
- History of, or current diagnosis of, catastrophic antiphospholipid syndrome (APS).
- History of recurrent infection requiring hospitalization and IV antibiotics.
- COVID-19 infection.
- Any history of an anaphylactic reaction to human proteins, or monoclonal antibodies.
- At screening, if participants do not meet the eligibility criteria assessed based on laboratory test results e.g tests for total bilirubin, serum creatinine etc.
NOTE: Other protocol defined Inclusion/Exclusion criteria may apply
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Tratamento
- Alocação: Randomizado
- Modelo Intervencional: Atribuição Paralela
- Mascaramento: Dobro
Número de braços
Armas e Intervenções
Grupo de Participantes / BraçoGrupo de Participantes / Braço |
Intervenção / TratamentoIntervenção / Tratamento |
|---|---|
|
Experimental: Anifrolumab
Participants will receive anifrolumab as a SC injection from Week 0/Day 1 up to Week 51. |
Anifrolumab will be provided as a solution for injection in accessorized pre-filled syringe (aPFS). |
|
Comparador de Placebo: Placebo
Participants will receive placebo as a SC injection from Week 0/Day 1 up to Week 23. From Week 24 the participants will receive anifrolumab up to and including Week 51. |
Matching placebo solution for injection in aPFS. |
O que o estudo está medindo?
Medidas de resultados primários
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Number of participants with a 70% reduction relative to baseline in the Cutaneous Lupus Erythematosus Disease Area and Severity Index-Activity (CLASI-A) score
Prazo: At Week 24
|
The CLASI is a validated index used for assessing the cutaneous lesions of SLE. It consists of 2 separate scores: i) activity of the disease, and ii) measure of damage. The CLASI instrument will be used at each study visit to capture individual skin manifestation scores. CLASI-70 responder (Yes/No) is defined as a participant who achieves a 70% reduction relative to baseline in CLASI-A score. Otherwise, the participant is considered a non-responder. |
At Week 24
|
Medidas de resultados secundários
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Change from baseline in total CLASI-A score
Prazo: At Week 24
|
The CLASI-A is a validated index used for assessing the cutaneous lesions of SLE. |
At Week 24
|
|
Number of participants with CLASI-70 response
Prazo: At Week 12
|
The CLASI is a validated index used for assessing the cutaneous lesions of SLE. CLASI-70 responder is defined as a participant who achieves a 70% reduction relative to baseline in CLASI-A score. Otherwise, the participant is considered a non-responder. |
At Week 12
|
|
Number of participants with ≥ 7-point reduction from baseline in CLASI-A total score
Prazo: At Week 12
|
The CLASI is a validated index used for assessing the cutaneous lesions of SLE. A 7-point reduction CLASI-A is established as clinically meaningful improvement in disease for CLE and as being impactful for patients. |
At Week 12
|
|
Number of participants with CLASI-50 response
Prazo: At Week 12 and Week 24
|
The CLASI is a validated index used for assessing the cutaneous lesions of SLE. CLASI-50 responder is defined as a responder (yes/no) is defined as a participant who achieves at least a 50% reduction relative to baseline in CLASI-A score. Otherwise, the participant is a non-responder. |
At Week 12 and Week 24
|
|
Number of participants who are sustained CLASI-70 responders
Prazo: Up to Week 52
|
The CLASI is a validated index used for assessing the cutaneous lesions of SLE. CLASI-70 responder is defined as a participant who achieves a 70% reduction relative to baseline in CLASI-A score. Otherwise, the participant is considered a non-responder. Amongst participants randomized to anifrolumab, the number of participants who maintained a CLASI-70 response from Week 24 up to Week 52 will be evaluated. |
Up to Week 52
|
|
Serum trough (pre-dose) concentrations of anifrolumab
Prazo: Double-blind: Pre-dose on Day 1 (Week 0), Weeks 1, 4, 12, 24; Open-label: Weeks 40, and 52 or early discontinuation visit [EDV] and follow-up visit (13 Weeks after last dose)
|
The Ctrough of subcutaneously administered anifrolumab in participants with chronic and/or subacute CLE will be evaluated. |
Double-blind: Pre-dose on Day 1 (Week 0), Weeks 1, 4, 12, 24; Open-label: Weeks 40, and 52 or early discontinuation visit [EDV] and follow-up visit (13 Weeks after last dose)
|
|
Number of participants with positive antidrug antibody
Prazo: Double-blind: Pre-dose on Day 1 (Week 0), Weeks 4, 12, and 24; Open-label: Pre-dose on Weeks 40, and 52 or EDV and follow-up visit (13 weeks after last dose)
|
The immunogenicity of subcutaneously administered anifrolumab in participants with chronic and/or subacute CLE will be evaluated. |
Double-blind: Pre-dose on Day 1 (Week 0), Weeks 4, 12, and 24; Open-label: Pre-dose on Weeks 40, and 52 or EDV and follow-up visit (13 weeks after last dose)
|
|
Percent change from baseline in suppression of the Interferon 21-gene
Prazo: Double-blind: Day 1 (Week 0), Week 1, 4, 12, and 24; Open-label; Week 40 and 52 or EDV and follow-up visit (13 weeks after last dose)
|
The pharmacodynamics of subcutaneously administered anifrolumab in participants with chronic and/or subacute CLE will be evaluated. |
Double-blind: Day 1 (Week 0), Week 1, 4, 12, and 24; Open-label; Week 40 and 52 or EDV and follow-up visit (13 weeks after last dose)
|
|
Change from baseline in Skindex-29+3 Symptom domain scores
Prazo: At Week 24
|
The Skindex-29+3 is based on a previous instrument, the Skindex-29 and has been modified to include items related to CLE. The instrument consists of 33 items, which are used to calculate 4 domains: Symptoms (7 items), Emotions (10 items), Functioning (12 items), and Lupus-specific (3 items). The remaining item asks the participants to rate how often they worry about side effects from treatment; however, this item is not used to calculate the domain scores. The response options are on a 5-point verbal rating scale, ranging from 1 (Never) to 5 (All the time). The instrument has a recall period of the previous 4 weeks. Each domain score ranges from 0 to 100 points, with higher scores indicating worse health-related quality of life. |
At Week 24
|
|
Change from baseline in Skindex-29+3 Emotion domain scores
Prazo: At Week 24
|
The Skindex-29+3 is based on a previous instrument, the Skindex-29 and has been modified to include items related to CLE. |
At Week 24
|
|
Change from baseline in Skindex-29+3 Function domain scores
Prazo: At Week 24
|
The Skindex-29+3 is based on a previous instrument, the Skindex-29 and has been modified to include items related to CLE. |
At Week 24
|
|
Change from baseline in Skindex-29+3 Lupus-Specific domain scores
Prazo: At Week 24
|
The Skindex-29+3 is based on a previous instrument, the Skindex-29 and has been modified to include items related to CLE. |
At Week 24
|
|
Change from baseline in Skindex-29+3 Total score
Prazo: At Week 24
|
The Skindex-29+3 is based on a previous instrument, the Skindex-29 and has been modified to include items related to CLE. |
At Week 24
|
|
Time from IP start date to CLASI-70 response.
Prazo: From Week 0/Day 1 up to Week 24
|
To assess the efficacy of anifrolumab compared with placebo on the onset of reduction in skin manifestations in participants with chronic and/or subacute CLE. |
From Week 0/Day 1 up to Week 24
|
|
Time from IP start date to CLASI-50 response.
Prazo: From Week 0/Day 1 up to Week 24
|
To assess the efficacy of anifrolumab compared with placebo on the onset of reduction in skin manifestations in participants with chronic and/or subacute CLE. |
From Week 0/Day 1 up to Week 24
|
Outras medidas de resultado
Outras medidas de resultado
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Number of participants with adverse events
Prazo: Screening (up to and including 42 days before Day 1) until Safety Follow-up Period (12 weeks from Week 52/EDV)
|
To evaluate the safety and tolerability of anifrolumab compared with placebo in participants with CLE. |
Screening (up to and including 42 days before Day 1) until Safety Follow-up Period (12 weeks from Week 52/EDV)
|
Colaboradores e Investigadores
Patrocinador
Patrocinador
Colaboradores
Colaboradores
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Real)
Início do estudo
Conclusão Primária (Real)
Conclusão Primária
Conclusão do estudo (Estimado)
Conclusão do estudo
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Primeira postagem
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última Atualização Postada
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Última verificação
Mais Informações
Termos relacionados a este estudo
Palavras-chave
Termos MeSH relevantes adicionais
Outros números de identificação do estudo
Outros números de identificação do estudo
- D346BC00001
- 2021-003698-70 (Número EudraCT)
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
Descrição do plano IPD
Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal Vivli.org. All requests will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
"Yes", indicates that AZ are accepting requests for IPD, but this does not mean all requests will be approved.
Prazo de Compartilhamento de IPD
AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA/PhRMA Data-Sharing Principles. For details of our timelines, please refer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
Critérios de acesso de compartilhamento IPD
When a request has been approved AstraZeneca will provide access to the anonymized individual patient-level data via secure research environment Vivli.org. A Signed Data Usage Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information.
Tipo de informação de suporte de compartilhamento de IPD
- PROTOCOLO DE ESTUDO
- SEIVA
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .